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Introduction
Hypercalcaemia is not uncommon in clinical 
practice. The majority of cases are accounted for by 
hyperparathyroidism and malignancy. The patient 
discussed below presented with an unusual case of 
hypercalcaemia.
Case report
A 56-year-old Caucasian man with a 30-year history 
of tophacious gout, initially proven by the aspiration 
of monosodium urate crystals from an inflamed joint, 
presented to the nephrology department after being 
diagnosed with stage 5 chronic kidney disease. He 
had been diagnosed with hypertension five years 
prior, by which stage he was already suffering from 
chronic kidney disease. His presenting complaints 
included nocturia, constipation without any weight 
changes and paraesthaesia of his feet. At the time of 
the consultation, his medication included allopurinol 
600 mg daily, colchicine 0.5 mg twice daily as needed 
and Adalat XL® 90 mg daily.
A physical examination revealed multiple gouty tophi 
and destructive arthropathy of both hands. Decreased 
vibration, fine touch sensation and diminished ankle 
reflexes (graded as 1 + bilaterally) were suggestive of a 
peripheral neuropathy in the lower limbs. A fundoscopy 
revealed grade 1 hypertensive retinopathy. The rest of 
the physical examination was unremarkable.
Blood tests showed normocytic, normochromic 
anaemia with a haemoglobin value of 12.1 g/dl. The 
uric acid level was 0.44 mmol/l and the patient had a 
normal 24-hour urinary uric acid of 1.6 mmol. Twenty-
four-hour creatinine clearance values were 12.4 ml/
minute, 11.6 ml/minute and 13.1 ml/minute respectively. 
Potassium levels and acid-base status were normal. The 
corrected serum calcium was elevated to 3.05 mmol/l, 
which was confirmed by an elevated ionised calcium 
of 1.68 mmol/l. Phosphate was also elevated to 
1.66 mmol/l. Thyroid functions were normal.
A chest X-ray revealed only osteopaenia and kyphosis 
of the thoracic spine, while an X-ray of the hands 
evidenced the destructive uric acid arthropathy 
(Figure 1). 
A renal ultrasound showed a left kidney size of 
11.1 x 4.9 x 4.7 cm, and a right kidney measuring 
10.5 x 4.8 x 5 cm. Both kidneys displayed loss of 
corticomedullary differentiation, and there was no 
evidence of hypdronephrosis or hydroureter.
A decision was made to conduct further investigations 
of the patient’s hypercalcaemia aetiology. A careful 
review of the history revealed no medication or 
supplementation which could have contributed 
to the hypercalcaemia. The serum parathyroid 
hormone (PTH) was suppressed to < 0.3 ng/l, excluding 
hyperparathyroidism as the aetiology for the hyper-
A challenging case of hypercalcaemia
Ueckermann V, MBChB, MMed(Int) 
Consultant, Department of Internal Medicine, Steve Biko Academic Hospital; University of Pretoria, Pretoria
Correspondence to: Veronica Ueckermann, e-mail: ueckermannv@live.com
Keywords: gout, hypercalcaemia, end-stage kidney disease
 Peer reviewed. (Submitted: 2012-10-08. Accepted: 2013-01-07.) © SEMDSA JEMDSA 2013;18(1):68-70
L: left, R: right
Figure 1: Plain radiograph of the hands, showing destructive 
gouty arthritis affecting the wrists and small joints of the hands
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calcaemia. The daily urine calcium excretion was 
appropriately elevated to 8.9 mmol/24 hours. 
In view of the patient’s age, the possibility of malignancy-
associated hypercalcaemia was considered. It was 
not possible to perform PTH-related peptide in our 
laboratory setting. Serum protein electrophoresis was 
normal, as were prostate-specific antigen values (for 
his age), while a colonoscopy and gastroscopy did 
not reveal any malignancy. A computed tomography 
scan of the patient’s chest revealed calcification of the 
thoracic aorta and bilateral axillary lymph nodes. The 
largest measured 1 x 1.6 cm. An excision biopsy of one 
of the nodes was performed and found to be reactive 
in appearance, with no features of malignancy. The 
patient underwent fluorodeoxyglucose (FDG)-positron 
emission tomography scanning, which was consistent 
with the arthritis and reactive lymph nodes.
Endocrinological causes, including thyrotoxicosis, 
pheochromocytoma and adrenal insufficiency, 
were excluded. Consideration was given to granulo-
matous disease as the aetiology. The patient’s 
1,25-dihydroxyvitamin D levels were elevated at 
70.2 ng/dl, with a normal 25-hydroxyvitamin D level. 
There was no clinical or radiological evidence to 
support the diagnosis of sarcoidosis. Induced sputum 
cultures were negative for tuberculosis.
It was postulated that chronic tophaceous gout was 
the aetiology for this patient’s hypercalcaemia. The 
mechanism was extrarenal, PTH-independent calcitriol 
production by activated mononuclear cells within the 
granuloma. 
The patient was treated with prednisone 0.5 mg/kg and 
two weeks later, his ionised calcium had normalised 
to 1.18 mmol/l, while his 1,25-dihydroxyvitamin D had 
normalised to 22 ng/l. This steroid response would 
be observed with any granulomatous cause of 
hypercalcaemia.
In the absence of any other cause of the 
hypercalcaemia, it was postulated that the index 
patient presented with hypercalcaemia secondary to 
chronic tophaceous gout. The hypercalcaemia, renal 
failure and colchicine could have contributed to his 
peripheral neuropathy.
Discussion
Hypercalcaemia is a relatively common problem in 
clinical medicine. The majority of cases (over 90%) 
can be accounted for by hyperparathyroidism or 
malignancy.1 
The initial step in determining the aetiology of 
hypercalcaemia is to differentiate PTH-mediated 
causes thereof (including primary hyperparathyroidism 
and familial hyperparathyroid syndromes) from non-
PTH-mediated hypercalcaemia (of which malignancy, 
vitamin D intoxication and granulomatous disease are 
the most common aetiologies).
Hypercalcaemia that is associated with malignancy is 
one of the most common causes of non-PTH-mediated 
hypercalcaemia. Malignancy is generally associated 
with a more recent onset of hypercalcaemia and 
is more likely to be symptomatic. The diagnosis of 
hypercalcaemia of malignancy can be confirmed 
by demonstrating an elevated serum concentration 
of PTH-related protein, while levels of PTH and 
1,25-dihydroxyvitamin D are generally suppressed.2
The vitamin D metabolite 25-hydroxyvitamin D is 
generally elevated in vitamin D intoxication.3 The 
metabolite 1,25-dihydroxyvitamin D may be increased 
by intake of this metabolite or by extrarenal production 
in the case of granulomatous disease, such as 
sarcoidosis or lymphoma. 
Rarer causes for hypercalcaemia include bone 
resorption, like that which occurs in thyrotoxicosis,4 
multiple myeloma5 or immobilisation.6 Increased intake 
of calcium can lead to hypercalcaemia in patients 
with renal insufficiency.
Other causes of hypercalcaemia include the 
use of lithium, teriparatide, excess vitamin A7 
or theophylline toxicity. Endocrine-associated 
conditions with hypercalcaemia include acromegaly, 
pheochromocytoma8 and adrenal insufficiency.9,10 
Generally, these are associated with other clinical 
features of the underlying disease.
Urinary calcium excretion may be decreased in 
the face of hypercalcaemia if the aetiology is 
familial hypocalciuric hypercalcaemia, the milk-
alkali syndrome associated with calcium carbonate 
consumption, and with the use of thiazide diuretics.
A case report by Sachdeva et al11 described the 
presentation of hypercalcaemia in a Caucasian man 
with chronic tophaceous gout. In this case, as with 
our patient, extensive workup of the aetiology for 
the hypercalcaemia revealed a low PTH, negative 
PTH-related protein, normal thyroid function tests, no 
evidence of malignancy, and negative blood, urine 
and sputum cultures. Endocrinological causes of 
the hypercalcaemia were excluded and a gallium 
scan revealed increased uptake in areas of gouty 
arthritis involvement. The authors of this case study 
postulated that the tophaceous gout was responsible 
for the hypercalcaemia. The suggested mechanism is 
extrarenal, PTH-independent calcitriol production by 
activated mononuclear cells within the granuloma. 
Monosodium urate crystals are thought to serve as the 
inciting antigen that leads to an intense inflammatory 
reaction of macrophages, lymphocytes and giant 
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cells. The patient was treated with systemic steroids 
which resulted in normalisation of his serum calcium 
levels.
In the index patient, none of these usual causes of 
hypercalcaemia could be established, on grounds 
of either clinical or special investigation. It would be 
of interest to test serum calcium levels in all patients 
with chronic tophaceous gout to establish whether 
hypercalcaemia is a common association.
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Abstract
Objectives: Carotid intima-media thickness (CIMT) is a surrogate marker of subclinical atherosclerosis and a predictor 
of cardiovascular events. Few studies in Africa have evaluated CIMT and its associations in people with type 2 
diabetes mellitus. This study measured CIMT in a sample of mainly black South African patients with type 2 diabetes 
mellitus, and evaluated the association of demographic and clinical risk factors with CIMT.
Design: Cross-sectional study.
Setting: Kalafong Hospital, a large community hospital in Pretoria that mainly serves an urban black community.
Subjects: Patients with type 2 diabetes mellitus.
Outcome measures: We evaluated clinical, biochemical and CIMT ultrasound measurements in a standardised 
fashion.
Results: In 185 patients, the univariate significant predictors of mean far-wall CIMT were age [beta 0.007 (standard 
error 0.001)], systolic blood pressure [beta 0.001 (standard error 0.000)] and inverse serum creatinine [beta -8.15 
(standard error 3.23)]. Low-density lipoprotein cholesterol, apolipoprotein A-1, apolipoprotein B:A-1 ratio and 
apolipoprotein B:A-1 ratio > 1.2 all had p-values below 0.1, but above 0.05. Age had the largest R-squared (20%). 
The multivariate models did not explain more of the variation in CIMT than did age alone.
Conclusion: Lipid parameters were related to CIMT in our study population. However, this did not reach statistical 
significance in this relatively small sample, and lipids added very little to the variability of CIMT compared with age 
alone.
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